Clinomics Aims to Become Europe’s No.1 in Early Colorectal Cancer Diagnosis Based on Liquid Biopsy

Clinomics announced on the 5th that it is accelerating the entry of its blood-based early colorectal cancer detection service, ColonAiQ, into the European market.

A company representative stated, "Clinomics' European branch has already obtained 'ISO 9001 certification' and simultaneously received approval from the Hungarian government for ColonAiQ," adding, "Recently, we signed service supply contracts for ColonAiQ with 12 large general hospitals and screening centers located in Hungary."

They continued, "Efforts to build infrastructure to generate demand for the blood-based early colorectal cancer detection service are expected to lead to the full-scale generation of sales and profits from the cancer early detection business after the fourth quarter of this year."

Since its establishment in 2021, Clinomics' European branch has focused on clinical research and business development of non-invasive liquid biopsy technology. Actively utilizing the technological capabilities and R&D infrastructure of its Korean headquarters, it recently launched the genetic diagnostics (Clinomics Diagnostics) division in Budapest, Hungary, centered on experts with specialization and experience in this field. The goal is to introduce and continuously develop the latest diagnostic methods based on liquid biopsy and multi-omics to elevate precision medicine to a higher level and provide extensive diagnostic services across pan-European countries.

Clinomics is undertaking various activities to establish and target a foothold in the European market. First, it is building R&D partnerships with major national university hospitals and research institutes in Hungary, including the University of Debrecen. By joining the European Liquid Biopsy Society (ELBS), it is expanding its research market through networks in liquid biopsy societies and industries. It is also focusing on establishing a growth foundation and securing profitability by distributing and selling the CD-Prime system and products in multiple European countries, as well as launching and increasing sales of the ColonAiQ colorectal cancer early detection diagnostic product.

Byungchul Kim, CEO of Clinomics, said, "Clinomics, as a liquid biopsy specialist company, has been rapidly launching advanced cancer diagnostic products in the global market and commercializing early cancer detection services." He added, "Through a strategic partnership with Singlera Genomics in the United States, we are launching the ColonAiQ colorectal cancer screening service starting from our Hungarian branch, concentrating our business capabilities to achieve the number one position in the early colorectal cancer detection service business in Europe, where colorectal cancer mortality is high, by 2025."

This content was produced with the assistance of AI translation services.